Spectral Diagnostics (Canada) acquires septic shock rights:
This article was originally published in Clinica
Spectral Diagnostics (Canada) has acquired patent-pending technology for early septic shock detection. The royalty- bearing deal also includes a collaborative research agreement with the Toronto Hospital team that developed the test. Spectral intends to develop a point-of-care test for critical care unit use. Septic shock affects around 400,000 North Americans every year. Treatment costs $5-10,000 million in the US alone.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.